drugset
drugset / Trial / NCT01133431

The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea

NCT01133431 ↗

Phase 1 Completed 24 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverSingle-blind

Summary

To assess the pharmacokinetic Interaction between CKD-501 and sulfonylurea (Glimepiride) in healthy male subjects.

Timeline

Start
2010-05
Primary completion
2010-06
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Glimepiride Small molecule 4 mg —
Subject Lobeglitazone Small molecule 0.5 mg —

Indications

No indication recorded.